Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1813-1832
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1813
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1813
Figure 1 Traffic light plot showing the risk of bias of the two completed studies.
Figure 2 Summary plot of the risk of bias assessment of the two completed studies.
Figure 3 Preferred reporting items for systematic reviews and meta-analyses diagram.
Figure 4 Distribution of study sites.
- Citation: Ahmed F, Onwumeh-Okwundu J, Yukselen Z, Endaya Coronel MK, Zaidi M, Guntipalli P, Garimella V, Gudapati S, Mezidor MD, Andrews K, Mouchli M, Shahini E. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World J Gastrointest Oncol 2021; 13(11): 1813-1832
- URL: https://www.wjgnet.com/1948-5204/full/v13/i11/1813.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i11.1813